Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics, Inc. (RAPP) has experienced significant stock price movements, with substantial increases of 132.69% and 144.28% over the past six months. Truist Securities initiated coverage with a "Buy" rating and a $44.00 price target in September 2025. JMP Securities reiterated its "Market Outperform" rating and a $77.00 price target in September 2025. The stock soared by 62% in a single week after meeting its Phase II epilepsy study goals. RAPP reached its all-time high of $42.27 USD on September 8, 2025, and its all-time low of $6.43 USD on March 4, 2025.

Demand seasonality is not applicable to Rapport Therapeutics, Inc. at this time, as it is a clinical-stage biopharmaceutical company without commercialized products.

Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule product candidates for central nervous system (CNS) disorders. They are advancing a pipeline of therapeutic programs targeting conditions like focal onset epilepsy, pain, bipolar disorder, and hearing disorders. A key product candidate is RAP-219, a clinical-stage small molecule targeting TARPy8 for epilepsy treatment.

Rapport Therapeutics, Inc. is headquartered in Boston, Massachusetts. Its geographic footprint is centered around its research and development operations and clinical trial sites.

Information specifically detailing Rapport Therapeutics, Inc.'s brand reputation was not available in the provided search results. Reputation is often closely tied to the success and integrity of its scientific research and clinical trials.

The ownership of Rapport Therapeutics, Inc. (RAPP) includes institutional, retail, and individual investors. Institutional investors hold approximately 20.85% to 26.22% of the company's stock, while insiders hold around 7.29%. Major institutional owners and shareholders include Trv Gp V, Llc, Fmr Llc, Arch Venture Corp, Cormorant Asset Management, LP, Capital International Investors, Johnson & Johnson, Sofinnova Investments, Inc., FDGRX - Fidelity Growth Company Fund, Price T Rowe Associates Inc /md/, Goldman Sachs Group Inc, Third Rock Ventures LLC, Fidelity Management & Research Co. LLC, and ARCH Venture Partners LLC.